INTELLECTUAL PROPERTY LICENSING RIGHTS (Details Narrative) - USD ($)	1 Months Ended		3 Months Ended		9 Months Ended		12 Months Ended
	Oct. 12, 2018	Aug. 20, 2018	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Naltrexone Implant Formulation [Member] \| Australia from Trinity Compound Solutions [Member]
Cash paid for acquisition		$ 10,000
Aggregate purchase price, Shares		20,000
Aggregate purchase price, value		$ 236,000
Patent acquired	$ 15,200
Patents [Member]
Amortization expense			$ 294	$ 295	$ 878	$ 875
Estimated useful lives	13 years
Accumulated amortization			2,342		2,342
Intellectual Property [Member]
Amortization expense			11,790		35,370
Estimated useful lives							5 years
Accumulated amortization			$ 47,360		$ 47,360		$ 11,990